By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
List view / Grid view
Filter the results
A study has shown that natural killer cells are linked to the protein GM-CSF, which causes inflammation, indicating a new target for rheumatoid arthritis.
Scientists have found that a molecule present in our blood, called C4BP (β-), could be used in a therapeutic capacity for lupus as well as potentially other autoimmune disorders.
New findings using CRISPR have shown that the IL-4 and IL-13 proteins can protect the body against inflammation from autoimmune diseases.
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
A new technique called ‘ubiquitin clipping’ has been created which could aid proteomics research and the development of new drugs for ubiquitination.
New study shows that a subset of follicular helper T cells contributes to the hyposialylation of autoantibodies in rheumatoid arthritis.
Series of molecules may provide more reliable relief with fewer side effects...
Despite being one of the more ancient aspects of immunity, therapeutic modulation of the innate immune system has rarely been attempted. Innate immunity is intrinsically linked to the generation of inflammation – necessary for signalling to the adaptive immune system but often self-perpetuating and over-exaggerated, leading to deleterious effects, including…
The neutrophil nanosponges can absorb and neutralise cytokines which play a role in the development of rheumatoid arthritis...
Epigenomic analyses may lead to other unexpected findings and novel therapeutic drug targets for many diseases
EBV may trigger some cases of lupus, say NIH-supported researchers...
Data from the Phase I study of collaborative industry partnership AMP are now available, meaning scientists can benefit from access to important research about Rheumatoid Arthritis and Systemic Lupus Erythematosus.